Patrick Campbell

A study from ESC Congress 2020 dove deeper into associations between specific biomarkers and risk of CV events in CAD patients with and without diabetes.

Lead investigator of the PARALLAX trial discusses whether he feels clinical data related to sacubitril/valsartan is strong enough to warrant prescribing it for HFpEF patients.

An analysis from ESC Congress 2020 is shedding further light on the effects of dulaglutide in patients with and without background metformin use.

Deepak Bhatt, MD, of Brigham and Women's Hospital, offers perspective on REDUCE-IT analyses and icosapent ethyl (Vascepa) data presented at ESC Congress 2020.

Full results of DAPA-CKD further inform clinicians on dapagliflozin and use of SGLT2 inhibitors in those with and without diabetes.

An ESC Congress 2020 study details the predictive value of galectin-3 levels for predicting risk of cardiovascular events in patients with type 2 diabetes

A podcast featuring the presenter of DAPA-CKD discussing results of the trial and how they inform use of dapagliflozin in patients with chronic kidney disease with and without type 2 diabetes.

Milton Packer, MD, discusses how EMPEROR-Reduced data influences the way clinicians view the SGLT2 inhibitor class and its uses.

A podcast featuring an interview with Prof. Kausik Ray centered around the latest inclisiran data presented at ESC Congress 2020.

A study from ESC Congress 2020 details the effects of initiating rhythm control within the first year of an atrial fibrillation diagnosis.

Lead investigator of IMPACT-AFib discusses the results of the study and how they inform clinicians on strategies to improve oral anticoagulant use.

A podcast featuring the lead investigator of a recent study examining impact of metabolic syndrome on COVID-19 outcomes in a pair of New Orleans-based hospitals.

Investigators found no benefit from the discontinuation of ACE inhibitors/ARBs in patients hospitalized with COVID-19 in a prospective, randomized, phase 4 trial.

A look at the state of insulin affordability in 2020 and how the ongoing pandemic has impacted the situation.

How good are your diagnostic skills? Test them with this month's Visual Dx quiz!

The MiniMed 770G becomes the first system to receive approval for children in this age group.

The largest and most comprehensive look at blood pressure therapies and cardiovascular disease risk to date is providing an overview of the effects of antihypertensive therapy at varying levels of baseline blood pressure.

Results of HOME-PE suggest an approach using HESTIA was noninferior to sPESI for patients with acute pulmonary embolism.

Analysis of the UK Biobank cohort details associations between increased HbA1c levels and risk of myocardial infarction in patients regardless of sex.

Full results of the DAPA-CKD trial from ESC Congress 2020 detail the effects of dapagliflozin (Farxiga) among chronic kidney disease patients with and without type 2 diabetes.

Results of the PARALLAX trial shed light on the effects of sacubitril/valsartan (Entresto) in patients with heart failure with preserved ejection fraction.

Results of the phase 3 EMPEROR-Reduced trial indicate the SGLT2 inhibitor empagliflozin was effective for patients with HFrEF regardless of whether the patients had diabetes or not.

An analysis of data from the New Bedford Cohort suggests exposure to endocrine-disrupting chemicals could increased risk of ADHD in adolescents.

Full data from the EVAPORATE trial presented at ESC Congress 2020 add further evidence of the cardiovascular benefits from use of icosapent ethyl.

A survey assessing burnout among nurses in Italy suggests more than one-third reported a high level of emotional exhaustion.

A meta-analysis examines the differences in HbA1c management, weight loss, and other factors associated with long- versus short-acting GLP-1 receptor agonists.

A pair of studies provides an overview of declines in use of cardiology services and patients presenting with adverse cardiovascular events during the pandemic.

A randomized trial found use of a closed-loop insulin delivery system was safe and effective in type 1 diabetics as young as 6 years of age.

A look at nationwide data from an 11-year period gives physicians a greater understanding of predictors, trends, and outcomes associated with stroke in hypertensive disorders of pregnancy.

New data from a pair of New Orleans-based hospitals suggests metabolic syndrome in Black patients with COVID-19 was associated with increased mortality.